CSL shares dive on lower profits and CEO departure
Regulatory and policy issues in China and the US, which delivers 50% of revenues, have hit Australia’s largest listed biotech company's sales of vaccine and blood plasma products.
Shares in Australia’s largest listed biotech company, CSL, plunged as much as 17% today after the company announced weak half-year earnings and the departure of its chief executive.
By mid-morning, the stock had staged a recovery, but was still down 10% to A$154.32 ($180.75) after CSL reported an
